INSMED Inc (INSM) Form 8-K — Oct 20, 2026
Insmed appointed Paul Hudson, former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health, as independent directors effective October 19, 2026. Hudson joins the Compensation Committee and Koppikar joins the Audit Committee, each receiving a $65,000 annual retainer, a $12,500 committee retainer, and RSUs valued at approximately $585,000. The hires add deep global biopharma commercial and financial expertise to the board as Insmed scales its respiratory and rare disease portfolio. Hudson led Sanofi through a sweeping transformation from September 2019 through February 2026 and previously ran Novartis Pharmaceuticals and AstraZeneca's North America business.
Key figures
- Rsu grant value each
- approximately $585,000
- Director cash retainer
- $65,000 annual (plus $12,500 committee retainer each)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.